– Darryl Sullivan has long history of service to AOAC –
Madison, WI, September 16, 2007 – Darryl Sullivan, Senior Manager of Food and Drug Analysis at Covance Inc. (NYSE: CVD), has been chosen as incoming President-elect for AOAC INTERNATIONAL, the company announced today.
AOAC is a private, not-for-profit association dedicated to the development and validation of analytical methods, the improvement of quality assurance procedures in laboratories, and the professional development of scientists. For over 100 years AOAC has led the industry in validating analytical methods, and has been at the forefront of ensuring worldwide confidence in analytical results. In terms of regulatory scrutiny, AOAC methods are the gold standard.
Sullivan was elected to his new post by the AOAC general membership at the organization's recent annual meeting in Anaheim, Calif. As President-elect, he will be working closely with the current AOAC President for the next year. Together they will be shaping the future directions for AOAC while administering all of the current association activities. In September 2008 Sullivan will assume the role of AOAC President.
Sullivan has been an active member of AOAC for 28 years and has held leadership positions in method validation with them for 20 years. Sullivan served as a member and Secretary of the AOAC Board of Directors, Chair of the AOAC Official Methods Board and as a member of the Board of Directors of the AOAC Research Institute.
Covance, a leader in food and dietary supplement testing for more than 70 years, has supported AOAC for more than 50 years, both by contributing analytical methods for validation and in participating as a laboratory for validating methods. As with Sullivan, Covance also supports AOAC through its employees. Wayne Ellefson, Senior Client Manager, is a Past-President of the Midwest Section, is a Fellow of AOAC, and is Chair of the Annual Meeting Technical Program Council.
The latest information about AOAC’s methods validation programs, training courses, membership, publications, and proficiency testing program can be found at http://www.aoac.org.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.3 billion, global operations in more than 20 countries, and more than 8,100 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.
Covance and the Covance logo are registered service marks of Covance in the United States and other countries.